What is Genetics Generation Advancement Sloan Ratio %?
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Dec. 2024, Genetics Generation Advancement has a Sloan Ratio of 4.62%, indicating the company is in the safe zone and there is no funny business with accruals.
Genetics Generation Advancement Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Genetics Generation Advancement Sloan Ratio % Chart
Competitive Comparison of Genetics Generation Advancement's Sloan Ratio %
For the Diagnostics & Research subindustry, Genetics Generation Advancement's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetics Generation Advancement's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetics Generation Advancement's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Genetics Generation Advancement's Sloan Ratio % falls into.
Genetics Generation Advancement Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Genetics Generation Advancement's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was 14.219 (Mar. 2024 ) + 18.185 (Jun. 2024 ) + 19.206 (Sep. 2024 ) + 3.088 (Dec. 2024 ) = NT$54.7 Mil.
Genetics Generation Advancement's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was 14.029 (Mar. 2024 ) + 6.419 (Jun. 2024 ) + 35.033 (Sep. 2024 ) + 26.135 (Dec. 2024 ) = NT$81.6 Mil.
Genetics Generation Advancement's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was 19.429 (Mar. 2024 ) + -68.894 (Jun. 2024 ) + -25.411 (Sep. 2024 ) + 14.46 (Dec. 2024 ) = NT$-60.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetics Generation Advancement (ROCO:4160) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2024, Genetics Generation Advancement has a Sloan Ratio of 4.62%, indicating the company is in the safe zone and there is no funny business with accruals.
Genetics Generation Advancement Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Genetics Generation Advancement's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Genetics Generation Advancement Business Description
Genetics Generation Advancement Corp is a Taiwan based company specialized in genetic testing and scientific information. It is engaged in providing services for the detection of genetic defects and prevention in newborns. Their main services include amniotic fluid chromosome chip screening, pre-implantation genetic diagnosis, and Molecular DNA testing diagnostics. The company is focused on the majority of areas of maternal precision medicine, pediatric disease diagnosis, drug-associated diagnosis, non-invasive cancer detection, and precise health management. The business units of the company are the Genetic Testing Unit and Informatics business unit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:4160 has been successfully added to your 